Your browser doesn't support javascript.
loading
Comparative effectiveness and cost-effectiveness of natalizumab and fingolimod in rapidly evolving severe relapsing-remitting multiple sclerosis in the United Kingdom.
Spelman, T; Herring, W L; Acosta, C; Hyde, R; Jokubaitis, V G; Pucci, E; Lugaresi, A; Laureys, G; Havrdova, E K; Horakova, D; Izquierdo, G; Eichau, S; Ozakbas, S; Alroughani, R; Kalincik, T; Duquette, P; Girard, M; Petersen, T; Patti, F; Csepany, T; Granella, F; Grand'Maison, F; Ferraro, D; Karabudak, R; Jose Sa, M; Trojano, M; van Pesch, V; Van Wijmeersch, B; Cartechini, E; McCombe, P; Gerlach, O; Spitaleri, D; Rozsa, C; Hodgkinson, S; Bergamaschi, R; Gouider, R; Soysal, A; Prevost, J; Garber, J; de Gans, K; Ampapa, R; Simo, M; Sanchez-Menoyo, J L; Iuliano, G; Sas, A; van der Walt, A; John, N; Gray, O; Hughes, S; De Luca, G.
Afiliación
  • Spelman T; MSBase Foundation, Melbourne, VIC, Australia.
  • Herring WL; Department of Clinical Neuroscience, Karolinska Institute, Stockholm, Sweden.
  • Acosta C; Health Economics, RTI Health Solutions, NC, USA.
  • Hyde R; Department of Neurobiology, Care Sciences and Society, Karolinska Institute, Stockholm, Sweden.
  • Jokubaitis VG; Value and Access, Biogen, Baar, Switzerland.
  • Pucci E; Medical, Biogen, Baar, Switzerland.
  • Lugaresi A; Department of Neuroscience, Central Clinical School, Monash University, Melbourne, Australia.
  • Laureys G; Neurology Unit, AST-Fermo, Fermo, Italy.
  • Havrdova EK; Dipartamento di Scienze Biomediche e Neuromotorie, Università di Bologna, Bologna, Italy.
  • Horakova D; IRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy.
  • Izquierdo G; Department of Neurology, University Hospital Ghent, Ghent, Belgium.
  • Eichau S; Department of Neurology and Center of Clinical Neuroscience, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic.
  • Ozakbas S; Department of Neurology and Center of Clinical Neuroscience, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic.
  • Alroughani R; Department of Neurology, Hospital Universitario Virgen Macarena, Seville, Spain.
  • Kalincik T; Department of Neurology, Hospital Universitario Virgen Macarena, Seville, Spain.
  • Duquette P; Izmir University of Economics, Medical Point Hospital, Izmir, Turkey.
  • Girard M; Division of Neurology, Department of Medicine, Amiri Hospital, Sharq, Kuwait.
  • Petersen T; Neuroimmunology Centre, Department of Neurology, Royal Melbourne Hospital, Melbourne, Australia.
  • Patti F; CORe, Department of Medicine, University of Melbourne, Melbourne, Australia.
  • Csepany T; CHUM and Universite de Montreal, Montreal, Canada.
  • Granella F; CHUM and Universite de Montreal, Montreal, Canada.
  • Grand'Maison F; Aarhus University Hospital, Arhus C, Denmark.
  • Ferraro D; Department of Medical and Surgical Sciences and Advanced Technologies, GF Ingrassia, Catania, Italy.
  • Karabudak R; UOS Sclerosi Multipla, AOU Policlinico "G Rodloico-San Marco", University of Catania, Italy.
  • Jose Sa M; Department of Neurology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.
  • Trojano M; Department of Medicine and Surgery, University of Parma, Parma, Italy.
  • van Pesch V; Department of General Medicine, Parma University Hospital, Parma, Italy.
  • Van Wijmeersch B; Neuro Rive-Sud, Quebec, Canada.
  • Cartechini E; Department of Neuroscience, Azienda Ospedaliera Universitaria, Modena, Italy.
  • McCombe P; Hacettepe University, Ankara, Turkey.
  • Gerlach O; Department of Neurology, Centro Hospitalar Universitario de Sao Joao, Porto, Portugal.
  • Spitaleri D; Faculty of Health Sciences, University Fernando Pessoa, Porto, Portugal.
  • Rozsa C; School of Medicine, University of Bari, Bari, Italy.
  • Hodgkinson S; Cliniques Universitaires Saint-Luc, Brussels, Belgium.
  • Bergamaschi R; Université Catholique de Louvain, Belgium.
  • Gouider R; University MS Centre, Hasselt-Pelt and Noorderhart Rehabilitation & MS, Pelt and Hasselt University, Hasselt, Belgium.
  • Soysal A; Neurology unit, AST Macerata, Macerata, Italy.
  • Castillo-Triviño; University of Queensland, Brisbane, Australia.
  • Prevost J; Royal Brisbane and Women's Hospital, Herston, Australia.
  • Garber J; Academic MS Center Zuyd, Department of Neurology, Zuyderland Medical Center, Sittard-Geleen, The Netherlands.
  • de Gans K; School for Mental Health and Neuroscience, Maastricht University, Maastricht, The Netherlands.
  • Ampapa R; Azienda Ospedaliera di Rilievo Nazionale San Giuseppe Moscati Avellino, Avellino, Italy.
  • Simo M; Jahn Ferenc Teaching Hospital, Budapest, Hungary.
  • Sanchez-Menoyo JL; Immune Tolerance Laboratory Ingham Institute and Department of Medicine, UNSW, Sydney, Australia.
  • Iuliano G; IRCCS Mondino Foundation, Pavia, Italy.
  • Sas A; Department of Neurology, LR18SP03 and Clinical Investigation Center Neurosciences and Mental Health, Razi University Hospital -, Mannouba, Tunis, Tunisia.
  • van der Walt A; Faculty of Medicine of Tunis, University of Tunis El Manar, Tunis, Tunisia.
  • John N; Bakirkoy Education and Research Hospital for Psychiatric and Neurological Diseases, Istanbul, Turkey.
  • Gray O; Hospital Universitario Donostia and IIS Biodonostia, San Sebastián, Spain.
  • Hughes S; CSSS Saint-Jérôme, Saint-Jerome, Canada.
J Med Econ ; 27(1): 109-125, 2024.
Article en En | MEDLINE | ID: mdl-38085684
There are several medications used to treat people with relapsing remitting multiple sclerosis, such as interferon-based therapies (Betaferon/Betaseron (US), Rebif, Avonex, Extavia), glatiramer acetate (Copaxone), teriflunomide (Aubagio), and dimethyl fumarate (Tecfidera), collectively named BRACETD. Other treatments for multiple sclerosis (MS) have a narrower use, such as natalizumab (Tysabri) or fingolimod (Gilenya), among others.This study objective was to assess how well natalizumab and fingolimod helped treating MS (clinical effectiveness) and subsequently estimate what the cost of these treatments is in comparison to the benefit they bring to people with rapidly evolving severe MS that use them in the United Kingdom (UK) (cost-effectiveness).We used an international disease registry (MSBase), which collects clinical data from people with MS in various centers around the world to compare the effectiveness of natalizumab, fingolimod and BRACETD treatments. We used a technique called propensity score matching to obtain results from comparable patient groups. People treated with natalizumab had better disease control, namely with fewer relapses and higher improvement on their disability level, than patients on fingolimod or BRACETD. Conversely, there were no differences between each group of people on a measure called disability worsening.Based on these clinical results, we built an economic model that simulates the lifetime costs and consequences of treating people with MS with natalizumab in comparison with fingolimod. We found that using natalizumab was less costly and was more effective compared to using fingolimod in UK patients.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Esclerosis Múltiple Recurrente-Remitente / Esclerosis Múltiple Límite: Humans País/Región como asunto: Europa Idioma: En Revista: J Med Econ Asunto de la revista: SERVICOS DE SAUDE Año: 2024 Tipo del documento: Article País de afiliación: Australia Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Esclerosis Múltiple Recurrente-Remitente / Esclerosis Múltiple Límite: Humans País/Región como asunto: Europa Idioma: En Revista: J Med Econ Asunto de la revista: SERVICOS DE SAUDE Año: 2024 Tipo del documento: Article País de afiliación: Australia Pais de publicación: Reino Unido